Cargando…
Acute bilateral central serous chorioretinopathy in a young male after the first dose of Oxford/AstraZeneca AZD1222 (Covishield) vaccine
We case of acute bilateral central serous chorioretinopathy (CSCR) after receiving the first dose of Covishield vaccine in a young, otherwise healthy male with no associated risk factors.
Autores principales: | Sindhu, Meenakshi, Bamotra, Ravi Kant, Singh, Sukhdev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228969/ https://www.ncbi.nlm.nih.gov/pubmed/36727385 http://dx.doi.org/10.4103/ijo.IJO_1629_22 |
Ejemplares similares
-
Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021) -
Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries
por: Sharun, Khan, et al.
Publicado: (2021) -
Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021) -
Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021) -
A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
por: Villa, Miguel, et al.
Publicado: (2021)